Clinical Trials · NCT02231762
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 57
- Start date
- Oct 2014
- Locations
- 10 sites, Austria, Germany
- Primary endpoint
- Disease Control Rate (DCR) After 6 Months